MedTrace Logo

Green Tea Extract in Treating Patients With Advanced Solid Tumors

NCT00003197 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers, as well as prevent the development of new cancers.

PURPOSE: Phase I trial to study the effectiveness of green tea extract in treating patients with advanced solid tumors that are refractory to standard therapy.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DIETARY_SUPPLEMENT

green tea extract

Sponsors & Collaborators

Principal Investigators

  • Vincent A. Miller, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-12-31
Primary Completion
2000-06-30
Completion
2000-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003197 on ClinicalTrials.gov